American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Chemomab Therapeutics Ltd. (CMMB)

$1.05 +5.00% NASDAQ: CMMB · 15-min delayed

TEL AVIV, L3
Public · NASDAQ: CMMB
12 employees

Visit website Follow

$10.0MMarket cap

-$9.0MNet income

12Employees

CMMBNASDAQ

2021IPO

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: CMMB
Employees: 12
IPO date: Mar 17, 2021
Headquarters: KIRYAT ATIDIM, BUILDING 7
TEL AVIV, L3 6158002
Phone: 972-77-331-0156
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: CMMB Nasdaq
SEC CIK: 1534248
EIN: 813676773
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Chemomab Therapeutics Ltd.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/chemomab-therapeutics-ltd/"><img src="https://americancompanies.com/badge/chemomab-therapeutics-ltd.svg" alt="Chemomab Therapeutics Ltd. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Chemomab Therapeutics Ltd. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: -$9.0M
Total assets: $13.8M
Market cap: $10.0M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: CMMB

$1.05 +5.00%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.00 $3.50

52-week range

Market cap: $10.0M
Shares outstanding: 9.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Mar 17, 2021

Chemomab Therapeutics Ltd. (CMMB) Stock Price

Reported a net loss of $9.0M.
Trading 70% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Chemomab Therapeutics Ltd..

Write a review

Newsroom

News about Chemomab Therapeutics Ltd.

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire Inc. · 2026-05-14 · positive Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire Inc. · 2026-03-19 · positive Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis GlobeNewswire Inc. · 2024-11-19 · positive Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire Inc. · 2024-08-21 · positive Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update GlobeNewswire Inc. · 2024-08-12 · positive Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know Zacks Investment Research · 2024-06-27

News & sentiment via Polygon.io

FAQ

Chemomab Therapeutics Ltd.: frequently asked questions

Is Chemomab Therapeutics Ltd. an American company?

Chemomab Therapeutics Ltd. is a US-based company headquartered in Tel Aviv, L3, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Chemomab Therapeutics Ltd. headquartered?

Chemomab Therapeutics Ltd. is headquartered in Tel Aviv, L3, United States.

Is Chemomab Therapeutics Ltd. publicly traded?

Yes — Chemomab Therapeutics Ltd. is a publicly traded company. Its stock trades under the ticker symbol CMMB on the NASDAQ.

What does Chemomab Therapeutics Ltd. do?

Chemomab Therapeutics Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore